Market capitalization | $1.61b |
Enterprise Value | $1.30b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 50.02 |
EV/Sales (TTM) EV/Sales | 2.07 |
P/S ratio (TTM) P/S ratio | 2.56 |
P/B ratio (TTM) P/B ratio | 2.23 |
Revenue growth (TTM) Revenue growth | 6.56% |
Revenue (TTM) Revenue | $629.74m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
20 Analysts have issued a 10x Genomics Inc - Ordinary Shares - Class A forecast:
20 Analysts have issued a 10x Genomics Inc - Ordinary Shares - Class A forecast:
Sep '24 |
+/-
%
|
||
Revenue | 630 630 |
7%
7%
|
|
Gross Profit | 414 414 |
9%
9%
|
|
EBITDA | -133 -133 |
12%
12%
|
EBIT (Operating Income) EBIT | -178 -178 |
7%
7%
|
Net Profit | -183 -183 |
18%
18%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company's products include Single Cell Gene Expression, Immune Profiling, CNV, ATAC, and Genome and Exome. 10X Genomics was founded by Serge Saxonov, Ben Hindson, Kevin D. Ness and Eduard Diviu Terradas on July 2, 2012 and is headquartered in Pleasanton, CA.
Head office | United States |
CEO | Serge Saxonov |
Employees | 1,259 |
Founded | 2012 |
Website | www.10xgenomics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.